Overview
Clear and confident health care decisions begin with questions. At Labcorp, we’re constantly in pursuit of answers. As a global leader of innovative and comprehensive laboratory services, we help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company works with health systems, providers, payers and biopharma organizations, and its laboratory network includes diagnostic reference and specialty labs, nonclinical labs and central labs.
Our more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Labcorp's scientific work spans areas such as oncology, neurology, rheumatology, cell and gene therapies, precision medicine, radiopharmaceuticals and vaccines, along with genetics, digital pathology and toxicology. Beyond healthcare and pharma, Labcorp also serves the crop and agricultural, chemical and environmental, and novel food safety testing industries.
For individuals, Labcorp operates walk-in lab locations with appointment scheduling, sells tests directly to consumers through Labcorp OnDemand, and offers the Marker by Labcorp Genetic Health Panel for inherited health risks. Its MyLabcorp mobile app uses AI to explain test results, track trends and manage appointments and billing, while clinicians can use an AI-enhanced Test Finder integrated into electronic health records. Learn more about Labcorp (NYSE: LH) at www.labcorp.com.
Private funding before listing
3 rounds. Latest: Post-IPO Debt, 16 Sep 2024.
| Date | Type | Amount |
|---|---|---|
| 16 Sep 2024 | Post-IPO Debt | $2B |
Office locations
Similar companies
- FortreaBiotechnology Research · Research Triangle Park, NC
- IqviaHospitals and Health Care · Durham, North Carolina
- ParexelPharmaceutical Manufacturing · Raleigh, North Carolina
- Quest DiagnosticsMedical and Diagnostic Laboratories · Secaucus, NJ
- Thermo Fisher ScientificBiotechnology Research · Waltham, MA
- Syneos HealthBiotechnology Research · Morrisville, NC
- ICON plcBiotechnology Research
- PfizerPharmaceutical Manufacturing · New York
- RocheBiotechnology Research
- Eli Lilly and CompanyPharmaceutical Manufacturing · Indianapolis, Indiana
Latest videos from Labcorp on YouTube
The five pillars of managing menopause
Behind the science that makes better health possible
Labcorp Perspectives Oncology: Surviving and Thriving with Cancer at 16
How fiber can help lower cholesterol and improve employee heart health
Recent posts from the Labcorp blog
- Breast Cancer Awareness Month is a reminder of the importance of informed care throughout the patient journey.
Plasma Detect ID MRD for breast cancer offers personalized molecular insights to support monitoring and help identify recurrence earlier for patients who have been treated for stage I-III breast cancer.
- BRCA1 and BRCA2 are only part of the hereditary breast cancer story.
Current guidelines support multigene panel testing for many patients who qualify for hereditary cancer testing. Variants associated with hereditary breast cancer can occur in genes beyond BRCA1/2, including PALB2, CHEK2, ATM, and TP53.